All News

Clinical trial data show results from switching to Delstrigo from other antiretroviral treatments for HIV.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Top news of the week from Specialty Pharmacy Times.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Emicizumab-kxwh (Hemlibra) is now the only prophylactic treatment approved for individuals with hemophilia A with and without factor VIII inhibitors.

Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.

Emicizumab-kxwh (Hemlibra) is now the only FDA-approved treatment for hemophilia A with and without factor VIII inhibitors.

A combination of 2 anti-HIV antibodies may be capable of suppressing HIV for months after treatment.

Artificial intelligence tool can analyze images of patients’ lung tumors, specify cancer types, and identify altered genes driving abnormal cell growth.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The increased risk of cancer is due in part to people living with HIV living longer, thanks to advances like antiretroviral therapy.

FDA officials have approved omadacycline (Nuzyra, Paratek), a modernized tetracycline, to treat adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

The FDA has approved sarecycline (Seysara, Almirall) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.

Study examines the role of liver macrophages as a long-lived HIV-1 cellular reservoir.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

The CDC suggests that providers can better inform women about the recommended maternal vaccines.

Given the knowledge that a single pharmacy position can attract hundreds of applications, you must do everything possible to keep yourself in contention.

The American Society of Health-System Pharmacists (ASHP) has published guidelines with practical recommendations and best practices for preventing patient harm from medication errors.

A recent survey concluded that strategies to increase workplace immunization, such as requiring vaccination or promoting free onsite vaccines, lead to increased vaccination rates.

In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.